FimmCyte Therapeutics

FimmCyte AG is a Swiss biotechnology company founded in 2022 as a spin-off from the University of Zurich and the University Hospital Zurich. The company specializes in developing targeted, first-in-class immunotherapy solutions to address chronic fibro-inflammatory diseases, with a primary focus on women's health and endometriosis. Its proprietary platform utilizes antibodies to identify and eliminate fibrotic tissue by targeting specific proteins overexpressed in diseased cells, aiming to correct immune system dysregulation rather than merely managing symptoms. The company's lead candidate, FMC2, is designed as a non-hormonal, disease-modifying treatment that seeks to address the root cause of endometriosis and potentially other fibrotic conditions.

By targeting the mechanisms underlying fibrosis and inflammation, FimmCyte aims to improve long-term outcomes and quality of life for patients suffering from conditions that currently lack curative therapies. The company has secured strategic support from investors and partners, including a research collaboration with Gedeon Richter to accelerate the clinical development of its pipeline. FimmCyte’s approach offers a potential paradigm shift in the treatment landscape by moving beyond traditional surgery or symptom-focused hormonal therapies, positioning the firm to address significant unmet medical needs in both women’s health and broader organ fibrosis markets.